News
Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.
The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.
European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback